Alec Barclay's most recent trade in T2 Biosystems Inc was a trade of 12,951 Common Stock done at an average price of $0.5 . Disclosure was reported to the exchange on April 8, 2022.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Purchase of securities on an exchange or from another person at price $ 0.50 per share. | 08 Apr 2022 | 12,951 | 181,944 (0%) | 0% | 0.5 | 6,476 | Common Stock |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2022 | 21,666 | 21,667 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2022 | 21,666 | 180,421 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.36 per share. | 14 Mar 2022 | 11,428 | 168,993 (0%) | 0% | 0.4 | 4,160 | Common Stock |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2022 | 168,488 | 336,976 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2022 | 168,488 | 247,633 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.45 per share. | 24 Feb 2022 | 88,878 | 158,755 (0%) | 0% | 0.4 | 39,888 | Common Stock |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2022 | 600,000 | 600,000 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2022 | 10,000 | 0 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2022 | 10,000 | 84,420 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.47 per share. | 20 Feb 2022 | 5,275 | 79,145 (0%) | 0% | 0.5 | 2,458 | Common Stock |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Sale of securities on an exchange or to another person at price $ 1.86 per share. | 17 Mar 2021 | 12,494 | 74,420 (0%) | 0% | 1.9 | 23,239 | Common Stock |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2021 | 21,667 | 43,333 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2021 | 21,667 | 86,914 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 505,464 | 505,464 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 10,000 | 72,527 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Alec Barclay | Chief Operations Officer | Sale of securities on an exchange or to another person at price $ 2.06 per share. | 21 Feb 2021 | 7,280 | 65,247 (0%) | 0% | 2.1 | 14,997 | Common Stock |